Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

14 results
Display

Fournier Gangrene in a Patient With Type 2 Diabetes Mellitus Treated With Dapagliflozin: A Case Report

Moon JY, Lee MR, Kim JH, Ha GW

Rare cases of Fournier gangrene (FG) possibly associated with sodium-glucose cotransporter 2 inhibitors have been reported. We present a case of a 66-year-old male patient with type 2 diabetes mellitus...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study

Lee SH, Min KW, Lee BW, Jeong IK, Yoo SJ, Kwon HS, Choi YH, Yoon KH

Background Glycemic variability is associated with the development of diabetic complications and hypoglycemia. However, the effect of sodium-glucose transporter 2 (SGLT2) inhibitors on glycemic variability is controversial. We aimed to examine...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Type 2 Diabetes

Choi JB, Yoo JM, Lee YJ, Kim JW, Lee SJ, Kim HY, Lee DS, Ko SH, Choe HS

Purpose: To investigate the effect of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, on inflammatory cytokines of urogenital tissue in a rat model of type 2 diabetes (T2DM) to infer pharmaceutical...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Acute Kidney Injury after Administering Dapagliflozin to a Diabetic Patient with Acute Cerebral Infarction

Park C, Lee EK, Kim SM, Cho JT, Lee DH, Lee Je, Jeon JH

Dapagliflozin is a recently developed oral anti-diabetic drug and SGLT2 inhibitor with well-known cardioprotective and renoprotective effects. Although a reduction of the glomerular filtration rate is induced by volume depletion...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prevention of Major Adverse Cardiovascular and Renal Outcomes with Sodium-Glucose Cotransporter 2 Inhibitors

Hong JH

Management of hyperglycemia limits progression of microvascular complications in type 2 diabetes mellitus (T2DM). According to large-scale randomized control studies to demonstrate the cardiovascular safety of sodium-glucose cotransporter 2 (SGLT2)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea

Park SH, Choi YJ, Rhee EJ, Huh KB

BACKGROUND: We aimed to retrospectively analyze the efficacy of 10 mg dapagliflozin (DAPA), which is a sodium-glucose cotransporter-2 inhibitor, in Korean patients with type 2 diabetes who visited a primary...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pharmacological evaluation of HM41322, a novel SGLT1/2 dual inhibitor, in vitro and in vivo

Lee KH, Lee SD, Kim N, Suh KH, Kim YH, Sim SS

HM41322 is a novel oral sodium-glucose cotransporter (SGLT) 1/2 dual inhibitor. In this study, the in vitro and in vivo pharmacokinetic and pharmacologic profiles of HM41322 were compared to those...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of dapagliflozin in patients with advanced diabetic kidney disease

Park HS, Jung YJ, Lee DY, Moon KH, Kim B, Kim HW

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are effective for overweight diabetic patients through the induction of glucosuria. However, SGLT2 inhibitors are not recommended for patients with advanced chronic kidney disease (CKD) because...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Review on Efficacy and Safety of SGLT2 Inhibitors as Add-on Therapy with Metformin

Jeong KH

BACKGROUND: The new type of diabetes treatment, SGLT2 inhibitors, has been approved for monotherapy and combination therapy, but medical insurance is only allowed in combination therapy with metformin, which is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparisons of Efficacy between Dapagliflozin and Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus Patients

Kang BK, An SH, Kim JY, Gwak HS

OBJECTIVE: This study aimed to compare effects on glycemic control and weight loss between the metformin/dapagliflozin combination and the metformin/sitagliptin combination in type 2 diabetic patients. METHODS: This study retrospectively reviewed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus

Cho HA, Jung YL, Lee YH, Lee YC, Lee JE, Lee SJ, Jeong SJ, Kim CH

BACKGROUND: Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces hyperglycemia and body weight by inhibiting renal glucose reabsorption. However, only a few studies have demonstrated efficacy of dapagliflozin for type 2 diabetic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effect and Safety of Dapagliflozin in Patients with Type 2 Diabetes: A Single-Institution Pharmacovigilance Review

Lee HW, Moon SJ, Han HS, Shin EJ, Baek JH, Han HJ, Cho YM, Kim KS

BACKGROUND: Dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, lowers blood glucose by reducing glucose reabsorption at the proximal renal tubule in an insulin-independent manner. We aimed to evaluate the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors and Incidence of Adverse Events in Patients with Type 2 Diabetes

Lee HJ, Geum MJ, Kim JS, Kim K, Son ES

BACKGROUND: Dapagliflozin is an oral selective inhibitor of sodium-glucose cotransporter 2(SGLT2), the kidney transporter chiefly responsible for glucose reabsorption from the glomerular filtrate. Because this mechanism does not require the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor

Jung CH, Jang JE, Park JY

Type 2 diabetes mellitus (T2DM) is a complex endocrine and metabolic disorder, and a major public health problem that is rapidly increasing in prevalence. Although a wide range of pharmacotherapies...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr